Holen Sie sich die Stockscreener-App
1.00
6.54%
-0.07
Handel nachbörslich:
1.03
0.03
+3.00%
Schlusskurs vom Vortag:
$1.07
Offen:
$1.05
24-Stunden-Volumen:
527.71K
Relative Volume:
0.28
Marktkapitalisierung:
$175.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$52.50M
KGV:
34.36
EPS:
0.0291
Netto-Cashflow:
$-4.13M
1W Leistung:
-16.67%
1M Leistung:
-15.25%
6M Leistung:
+228.30%
1J Leistung:
-61.83%
1-Tages-Spanne:
$1.00
$1.08
1-Wochen-Bereich:
$1.00
$1.22
52-Wochen-Spanne:
$0.2556
$4.78
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Firmenname
Tevogen Bio Holdings Inc
Sektor
Branche
Telefon
646-807-8832
Adresse
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Vergleichen Sie TVGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.00 | 175.05M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Eingeleitet | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Tevogen Bio Holdings Inc. SEC 10-K Report - TradingView
Tevogen Bio Holdings Delays Annual Report Filing - TipRanks
Thomas Butler steps down as Biomea CEO - BioCentury
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - The Manila Times
Tevogen Bio's Ambitious $2B Revenue Target Backed by Leadership Excellence and Key Hire - Stock Titan
Tevogen Bio appoints new head of government affairs By Investing.com - Investing.com South Africa
Tevogen Bio appoints new head of government affairs - Investing.com
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Quantisnow
Tevogen Bio Appoints David E. Banko as Global Head of - GlobeNewswire
Healthcare Access Expert Joins Tevogen Bio to Accelerate Multi-Therapeutic Commercial Launch - Stock Titan
TSX Continues Higher as U.S. Trade Policy Appears to Soften - The Globe and Mail
SPY ETF News, 3/21/2025 - The Globe and Mail
Meta Stock Dips Below $600: A Buying Opportunity or a Red Flag? - The Globe and Mail
Tevogen Bio CEO reinforces commitment to retention of equity capital - MSN
Tevogen Bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen Bio’s chief scientific officer sells $253,935 in stock - Investing.com India
Tevogen bio’s chief scientific officer sells $253,935 in stock - Investing.com
Tevogen Bio Holdings Officer Sells Shares to Cover Tax Obligations - TradingView
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 86.7% in February - Defense World
Tevogen Bio (NASDAQ:TVGN) Receives “Buy” Rating from D. Boral Capital - Defense World
Public market insider selling at Aura Minerals (ORA) - The Globe and Mail
Tevogen bio’s chief scientific officer sells shares worth $231,734 By Investing.com - Investing.com South Africa
Tevogen bio’s chief scientific officer sells shares worth $231,734 - Investing.com India
Tevogen Bio Files New US Patent for T Cell Vaccine Under Development -March 10, 2025 at 01:19 pm EDT - Marketscreener.com
Tevogen announces new patent filed for T cell vaccine - TipRanks
Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO - Marketscreener.com
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - The Manila Times
Tevogen Bio Files Patent for Innovative T Cell Vaccine Targeting Entire Viral Genome to Combat Mutations - Nasdaq
Tevogen Bio Files Patent for AI-Powered T Cell Vaccine with Military Applications - StockTitan
Have Tevogen Bio Holdings Insiders Been Selling Stock? - simplywall.st
Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft - Insider Monkey
Tevogen bio’s chief scientific officer sells shares totaling $250k By Investing.com - Investing.com South Africa
Tevogen Bio's CIO Mittul Mehta Discusses AI Innovations in Biotech at Proskauer Panel - Nasdaq
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel - GlobeNewswire
Can AI Transform Biotech? Tevogen's Tech Chief Reveals Next-Gen Strategy - StockTitan
Tevogen Bio’S CIO & Head Of Tevogen.AI, Mittul Mehta, Featured Speaker At Proskauer’S AI Discussion Panel - MENAFN.COM
Tevogen bio’s chief scientific officer sells shares totaling $250k - Investing.com
9 AI News Updates Investors Should Not Miss - Insider Monkey
D. Boral Capital Begins Coverage on Tevogen Bio (NASDAQ:TVGN) - Defense World
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential - Benzinga
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga India
Tevogen initiated with a Buy at D. Boral Capital - TipRanks
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - GlobeNewswire
Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant Funding - MarketScreener
Tevogen Bio Secures Additional $8 Million Grant from KRHP LLC to Advance AI-Driven Immunotherapy Developments - Nasdaq
How Tevogen Bio's $8M Grant Funding Strengthens Its AI-Powered Biotech Future - StockTitan
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - The Manila Times
Finanzdaten der Tevogen Bio Holdings Inc-Aktie (TVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):